File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Significance of isolated anti-HBc seropositivity by ELISA: Implications and the role of radioimmunoassay

TitleSignificance of isolated anti-HBc seropositivity by ELISA: Implications and the role of radioimmunoassay
Authors
Issue Date1992
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763
Citation
Journal Of Medical Virology, 1992, v. 36 n. 3, p. 180-183 How to Cite?
AbstractHepatitis B virus (HBV) surface antigen (HBsAg) and antibody to HBsAg (anti-HBs) are excellent markers for HBV infection and its immunity. The significance of isolated antibody to HBV core antigen (anti-HBc) seropositivity is not certain. To elucidate this, sera from 638 Chinese adult subjects, aged 18-52 years, seronegative for both HBsAg and anti-HBs, were tested for anti-HBc. Fifty-one (8%) were found to have an isolated anti-HBc seropositivity by ELISA, and all were negative for IgM-anti-HBc. The anti-HBc persisted in all subjects who attended follow-up for hepatitis B vaccination (n = 48) for a period of 8 months. These 48 subjects received 3 doses of hepatitis B vaccine (HB-VAX, 10 μg or 20 μg) at 0, 1, and 6 months: 72.9% developed a primary anti-HBs response (suggestive of a false-positive anti-HBc seropositivity), 4.2% developed an anamnestic or secondary anti-HBs response, and 22.9% did not develop an anti-HBs response. Increasing the cutoff point of the ELISA or reconfirmation with radioimmunoassay (RIA) reduced only a minor half of the false positives. This low specificity of anti-HBc ELISA/RIA, together with the high rate of anti-HBs response to hepatitis B vaccine, indicates that subjects with isolated anti-HBc seropositivity should be included in vaccination programs.
Persistent Identifierhttp://hdl.handle.net/10722/161926
ISSN
2015 Impact Factor: 1.998
2015 SCImago Journal Rankings: 1.015
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorLau, JYNen_US
dc.contributor.authorYeoh, EKen_US
dc.contributor.authorChang, WKen_US
dc.contributor.authorLin, HJen_US
dc.date.accessioned2012-09-05T05:16:05Z-
dc.date.available2012-09-05T05:16:05Z-
dc.date.issued1992en_US
dc.identifier.citationJournal Of Medical Virology, 1992, v. 36 n. 3, p. 180-183en_US
dc.identifier.issn0146-6615en_US
dc.identifier.urihttp://hdl.handle.net/10722/161926-
dc.description.abstractHepatitis B virus (HBV) surface antigen (HBsAg) and antibody to HBsAg (anti-HBs) are excellent markers for HBV infection and its immunity. The significance of isolated antibody to HBV core antigen (anti-HBc) seropositivity is not certain. To elucidate this, sera from 638 Chinese adult subjects, aged 18-52 years, seronegative for both HBsAg and anti-HBs, were tested for anti-HBc. Fifty-one (8%) were found to have an isolated anti-HBc seropositivity by ELISA, and all were negative for IgM-anti-HBc. The anti-HBc persisted in all subjects who attended follow-up for hepatitis B vaccination (n = 48) for a period of 8 months. These 48 subjects received 3 doses of hepatitis B vaccine (HB-VAX, 10 μg or 20 μg) at 0, 1, and 6 months: 72.9% developed a primary anti-HBs response (suggestive of a false-positive anti-HBc seropositivity), 4.2% developed an anamnestic or secondary anti-HBs response, and 22.9% did not develop an anti-HBs response. Increasing the cutoff point of the ELISA or reconfirmation with radioimmunoassay (RIA) reduced only a minor half of the false positives. This low specificity of anti-HBc ELISA/RIA, together with the high rate of anti-HBs response to hepatitis B vaccine, indicates that subjects with isolated anti-HBc seropositivity should be included in vaccination programs.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763en_US
dc.relation.ispartofJournal of Medical Virologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_US
dc.subject.meshHealth Personnelen_US
dc.subject.meshHepatitis B Antibodies - Blooden_US
dc.subject.meshHepatitis B Core Antigens - Immunologyen_US
dc.subject.meshHepatitis B Vaccinesen_US
dc.subject.meshHepatitis B Virus - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRadioimmunoassayen_US
dc.subject.meshSensitivity And Specificityen_US
dc.subject.meshVaccines, Syntheticen_US
dc.subject.meshViral Hepatitis Vaccines - Pharmacologyen_US
dc.titleSignificance of isolated anti-HBc seropositivity by ELISA: Implications and the role of radioimmunoassayen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/jmv.1890360306-
dc.identifier.pmid1532979-
dc.identifier.scopuseid_2-s2.0-0026544928en_US
dc.identifier.volume36en_US
dc.identifier.issue3en_US
dc.identifier.spage180en_US
dc.identifier.epage183en_US
dc.identifier.isiWOS:A1992HK71400005-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridYeoh, EK=35427828500en_US
dc.identifier.scopusauthoridChang, WK=37043471800en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats